[
  {
    "ts": "2026-01-30T13:00:00+00:00",
    "headline": "Kyowa Kirin to Regain Control of Rocatinlimab Development and Commercialization Program, Demonstrating Strong Commitment to Address High Unmet Medical Need in Atopic Dermatitis",
    "summary": "Kyowa Kirin affirms commitment to developing rocatinlimab as a life-changing differentiated asset with significant market potential.Rocatinlimab’s novel approach as an investigational T-cell rebalancing therapy directly targeting the OX40 receptor expressed on pathogenic T-cells shows potential to deliver long-term disease control in patients with moderate-to-severe atopic dermatitis (msAD).Regulatory submission is planned in the first half of 2026. TOKYO and PRINCETON, N.J., Jan. 30, 2026 (GLOB",
    "url": "https://finance.yahoo.com/news/kyowa-kirin-regain-control-rocatinlimab-130000920.html",
    "source": "GlobeNewswire",
    "provider": "yfinance",
    "raw": {
      "id": "be68371d-8351-3ddc-a36b-169201bfe1c9",
      "content": {
        "id": "be68371d-8351-3ddc-a36b-169201bfe1c9",
        "contentType": "STORY",
        "title": "Kyowa Kirin to Regain Control of Rocatinlimab Development and Commercialization Program, Demonstrating Strong Commitment to Address High Unmet Medical Need in Atopic Dermatitis",
        "description": "",
        "summary": "Kyowa Kirin affirms commitment to developing rocatinlimab as a life-changing differentiated asset with significant market potential.Rocatinlimab’s novel approach as an investigational T-cell rebalancing therapy directly targeting the OX40 receptor expressed on pathogenic T-cells shows potential to deliver long-term disease control in patients with moderate-to-severe atopic dermatitis (msAD).Regulatory submission is planned in the first half of 2026. TOKYO and PRINCETON, N.J., Jan. 30, 2026 (GLOB",
        "pubDate": "2026-01-30T13:00:00Z",
        "displayTime": "2026-01-30T13:00:00Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/globenewswire.com/318e320275c322b5804812b9152c197d",
          "originalWidth": 1165,
          "originalHeight": 224,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/xUyV1.3J81b9rw_djVyGsg--~B/aD0yMjQ7dz0xMTY1O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/globenewswire.com/318e320275c322b5804812b9152c197d.cf.webp",
              "width": 1165,
              "height": 224,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/DJy_GMupzqzBkpxdFYD5Ww--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/globenewswire.com/318e320275c322b5804812b9152c197d.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "GlobeNewswire",
          "url": "https://www.globenewswire.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/kyowa-kirin-regain-control-rocatinlimab-130000920.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/kyowa-kirin-regain-control-rocatinlimab-130000920.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "KYKOF"
            },
            {
              "symbol": "KYKOY"
            },
            {
              "symbol": "AMGN"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  }
]